Logo

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Share this

Eli Lilly Reports Results of Emgality (galcanezumab-gnlm) in Three P-III Studies for Chronic and Episodic Migraine

Shots:

  • The P-III studies include REGAIN and EVOLVE-1 & 2 assessing Emgality vs PBO in patients with chronic and episodic migraine respectively
  • Post-hoc analyses results: reductions in disability in chronic migraine (20.3% vs 13.9%); @6mos. little/no disability in episodic migraine (44.0% vs 26.5%); improvement in daily functioning
  • Emgality is a mAb targeting CGRP and has received EMA’s approval for the prophylaxis of migraine in Nov’2018 and FDA’s approval for migraine and episodic cluster headache in adults in Sept’2018 and Jun’2019 respectively

Click here to read full press release/ article

Ref: Lilly | Image: Eli Lilly


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions